Time to Expect More From Pharmacometrics

被引:4
|
作者
Barrett, Jeffrey S. [1 ,2 ]
机构
[1] Bill & Melinda Gates Med Res Inst, Cambridge, MA 02142 USA
[2] Crit Path Inst, Tucson, AZ 85718 USA
关键词
LABELING DECISIONS; DRUG APPROVAL; MODEL; IMPACT;
D O I
10.1002/cpt.1914
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacometrics (PMX) has matured over the past 4 decades and become an integral part of drug development. Whereas the industrialization(1) of the discipline continues to standardize and refine the deliverables, particularly those that become incorporated into regulatory submissions, PMX should still evolve further to embrace newer and complimentary methodologies and approaches as other quantitative sciences have. There are obvious adaptions that the discipline should embrace in order to achieve its potential.
引用
收藏
页码:1129 / 1131
页数:3
相关论文
共 50 条